KROS – keros therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
KROS Stock: What to Know About Rinvatercept in DMD [Yahoo! Finance]
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics (KROS) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00. They now have an "overweight" rating on the stock.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Form SCHEDULE 13G Keros Therapeutics, Inc. Filed by: BlackRock, Inc.
Form 4 Keros Therapeutics, Inc. For: Apr 02 Filed by: Seehra Jasbir
Form 144 Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Form 4/A Keros Therapeutics, Inc. For: Feb 24 Filed by: Cho Esther
Form SCHEDULE 13G/A Keros Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.